Eli Lilly's Orforglipron shines in Phase III trials, potentially leading diabetes and obesity treatment by 2026. See what to ...

Olema Pharmaceuticals, Inc.’s OLMA share price has dipped by 5.78%, which has investors questioning if this is right time to ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Major scientific discoveries can arise from simple decisions: say, by simply looking where virtually no one else has. Such ...

Relay Therapeutics, Inc.’s RLAY share price has surged by 5.63%, which has investors questioning if this is right time to sell.

The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.

The theoretical basis for and clinical experience with using oral serotonin type 3 (5-HT 3)-receptor antagonists for preventing chemotherapy-induced emesis are discussed. Evidence supports the ...

Mind Lab Pro has positioned itself as a universal nootropic designed to support multiple areas of brain health and ...

In part 4 of an interview with The American Journal of Managed Care®, Frederick L. Locke, MD, provides insight on the design ...